Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Guardant Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Guardant Health's regulatory disclosures and financial reporting.
Guardant Health director Roberto Mignone exercised a restricted stock unit award on July 21, 2026, converting 264 Restricted Stock Units into 264 shares of Common Stock at $0.00 per share. Following this transaction, he directly holds 9,746 Common shares and 7,128 Restricted Stock Units. The RSU grant, awarded on November 8, 2024, vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the subsequent three years. The transaction was not marked as made under a Rule 10b5-1 trading plan, as the related checkbox was left unchecked.
Guardant Health, Inc. director Manuel Hidalgo Medina reported the vesting and settlement of 232 Restricted Stock Units into 232 shares of common stock on July 17, 2026. After these transactions he directly holds 5,306 common shares and 5,569 remaining RSUs from a four-year grant awarded July 17, 2024.
Guardant Health director Tariq Musa reported transactions in company equity. On July 15, 2026, he converted 250 Restricted Stock Units into 250 shares of common stock at no cash cost, leaving 1,999 RSUs outstanding. On July 16, he sold 116 shares of common stock in an open-market sale at $163.29 per share and held 11,182 shares afterward.
Guardant Health, Inc. shareholder Musa Tariq is reported in a Form 144 as intending to sell an amount of 116 common shares through Charles Schwab & Co., Inc. on NASDAQ, with a referenced value of $18,942.00 and an associated date of July 16, 2026.
These securities are described as common stock acquired on July 15, 2026 via a Restricted Stock Lapse, categorized as Equity Compensation. The filing also lists securities sold during the past three months: amounts of 116 with dollar values of $9,840.00, $11,131.00 and $15,102.00 on April 16, May 18 and June 16, 2026, and an amount of 1,951 with a dollar value of $255,893.00 on June 22, 2026.
Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity tied to restricted stock units (RSUs). On 2026-07-01, several RSU awards vested and converted into a total of 7,063 shares of Guardant Health common stock at a stated price of $0.00 per share.
To cover tax obligations from this vesting, the company retained 3,707 shares at a price of $170.77 per share, according to the filing footnotes. These transactions reflect RSU vesting, derivative exercises, and tax withholding, not open-market purchases or sales.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity. On July 1, 2026, restricted stock units converted into a total of 4,020 shares of Common Stock, reflecting scheduled vesting of prior awards. The company retained 2,099 shares at $170.77 per share to cover Ms. Monroe’s tax withholding obligations, rather than through an open-market sale. Following these transactions, she continues to hold both common shares and unvested restricted stock units as part of her compensation.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported routine equity compensation activity. On 2026-07-01, several batches of restricted stock units vested and were converted into a total of 6,046 shares of common stock at a conversion price of $0.00 per share.
To cover associated tax obligations from this vesting, 3,066 shares of common stock were withheld by the company at a value of $170.77 per share, as described in the footnotes. These transactions reflect compensation-related vesting and tax withholding rather than open-market buying or selling.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported compensation-related equity activity involving restricted stock units. On July 1, 2026, RSU awards vested and were converted into a total of 7,414 shares of common stock, reflecting derivative exercises rather than open-market purchases.
To cover tax obligations arising from this vesting, 3,141 shares of common stock were retained by the company at a value of $170.77 per share, as noted in the footnotes. The transactions do not include any open-market buying or selling, and are characterized as routine equity compensation and tax withholding events.
Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity involving restricted stock units and related tax withholding. On July 1, 2026, several restricted stock unit awards converted into common stock, reflected as multiple exercise transactions.
In connection with the vesting, 4,318 shares of common stock were retained by Guardant Health at $170.77 per share to cover her tax withholding obligations, as described in the footnotes. Following these transactions, Chudova directly held 78,373 shares of Guardant Health common stock.
Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity involving restricted stock units that vested into common stock. On July 1, 2026, RSU conversions delivered 7,278 shares of common stock, while 3,914 shares were withheld at $170.77 per share to cover tax obligations, rather than sold in the open market.